Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3057% below fair value
$0.51−0.02 (-3.73%)
Close on Nov 16, 2026Market cap $78.16MP/E –Yield –
Coherus Oncology cash
Cash and short-term investments held at the end of each period.
Coherus Oncology's cash was $105.30M at Jun 30, 2026. For fiscal 2025 it was $172.13M, up 36.3% from the year before. Over ten years it grew 0.8% a year on average. The highest annual figure on record is $541.20M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.13M | +36.3% |
| FY2024 | Dec 31, 2024 | $126.25M | +6.8% |
| FY2023 | Dec 31, 2023 | $118.20M | -38.3% |
| FY2022 | Dec 31, 2022 | $191.68M | -54.1% |
| FY2021 | Dec 31, 2021 | $417.20M | -22.9% |
| FY2020 | Dec 31, 2020 | $541.20M | +204.6% |
| FY2019 | Dec 31, 2019 | $177.67M | +145.5% |
| FY2018 | Dec 31, 2018 | $72.36M | -43.4% |
| FY2017 | Dec 31, 2017 | $127.76M | +1.6% |
| FY2016 | Dec 31, 2016 | $125.79M | -20.9% |
| FY2015 | Dec 31, 2015 | $159.07M | +5.8% |
| FY2014 | Dec 31, 2014 | $150.39M | +280.2% |
| FY2013 | Dec 31, 2013 | $39.55M | +171.9% |
| FY2012 | Dec 31, 2012 | $14.55M | +89.3% |
| FY2011 | Dec 31, 2011 | $7.68M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $105.30M | -55.7% |
| Q1 FY2026 | Mar 31, 2026 | $167.05M | +102.1% |
| Q4 FY2025 | Dec 31, 2025 | $172.13M | +36.3% |
| Q3 FY2025 | Sep 30, 2025 | $191.66M | +95.7% |
| Q2 FY2025 | Jun 30, 2025 | $237.90M | +49.0% |
| Q1 FY2025 | Mar 31, 2025 | $82.67M | -68.2% |
| Q4 FY2024 | Dec 31, 2024 | $126.25M | +6.8% |
| Q3 FY2024 | Sep 30, 2024 | $97.95M | -25.3% |
| Q2 FY2024 | Jun 30, 2024 | $159.69M | +10.4% |
| Q1 FY2024 | Mar 31, 2024 | $260.23M | +103.2% |
| Q4 FY2023 | Dec 31, 2023 | $118.20M | -38.3% |
| Q3 FY2023 | Sep 30, 2023 | $131.08M | -54.3% |
| Q2 FY2023 | Jun 30, 2023 | $144.71M | -47.5% |
| Q1 FY2023 | Mar 31, 2023 | $128.09M | -60.7% |
| Q4 FY2022 | Dec 31, 2022 | $191.68M | -54.1% |
| Q3 FY2022 | Sep 30, 2022 | $286.81M | -38.8% |
| Q2 FY2022 | Jun 30, 2022 | $275.48M | -39.4% |
| Q1 FY2022 | Mar 31, 2022 | $325.68M | -18.5% |
| Q4 FY2021 | Dec 31, 2021 | $417.20M | -22.9% |
| Q3 FY2021 | Sep 30, 2021 | $468.71M | -6.9% |
| Q2 FY2021 | Jun 30, 2021 | $454.42M | -0.5% |
| Q1 FY2021 | Mar 31, 2021 | $399.50M | +106.7% |
| Q4 FY2020 | Dec 31, 2020 | $541.20M | +204.6% |
| Q3 FY2020 | Sep 30, 2020 | $503.43M | +195.3% |
| Q2 FY2020 | Jun 30, 2020 | $456.50M | +308.0% |
| Q1 FY2020 | Mar 31, 2020 | $193.30M | +100.5% |
| Q4 FY2019 | Dec 31, 2019 | $177.67M | +145.5% |
| Q3 FY2019 | Sep 30, 2019 | $170.50M | +45.5% |
| Q2 FY2019 | Jun 30, 2019 | $111.90M | -30.0% |
| Q1 FY2019 | Mar 31, 2019 | $96.40M | +1.3% |
| Q4 FY2018 | Dec 31, 2018 | $72.36M | -43.4% |
| Q3 FY2018 | Sep 30, 2018 | $117.20M | -21.9% |
| Q2 FY2018 | Jun 30, 2018 | $159.80M | +35.1% |
| Q1 FY2018 | Mar 31, 2018 | $95.20M | -45.5% |
| Q4 FY2017 | Dec 31, 2017 | $127.76M | +1.6% |
| Q3 FY2017 | Sep 30, 2017 | $150.10M | -6.0% |
| Q2 FY2017 | Jun 30, 2017 | $118.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $174.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $125.79M | – |
| Q3 FY2016 | Sep 30, 2016 | $159.68M | – |
See a number that looks wrong?